2 results
Approved WMOWill not start
The primary objective of this study is to determine if ambrisentan is effective in delaying disease progression and death in subjects with IPF.Secondary objectives include evaluation of the safety and effect of ambrisentan on development of…
Approved WMOWill not start
primary objectives:* Part 1 (dose escalation): To determine therecommended Phase 2 dose(s) (RP2D[s]) forTAR-210* Part 2 (dose expansion): To determine thesafety of TAR-210 administered at theRP2D(s)for up to 12 monthsSecondary objectives (Parts 1…